Google
AVLN — AVALYN PHARMA INC. COMMON STOCK (Healthcare >> Biotechnology)
AVLN FAQ
What is AVLN's ROE?
AVALYN PHARMA INC. COMMON STOCK reports a Return on Equity (ROE) of 0.00%.
What is AVLN's dividend yield?
AVALYN PHARMA INC. COMMON STOCK offers a dividend yield of 0.00%.
What is AVLN's Deepscope Quality Score?
Deepscope rates AVLN's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy AVLN?
Deepscope's AI Timing Score for AVLN is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does AVLN belong to?
AVALYN PHARMA INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 27.06
Price
0.07
(0.26%)
Day Change
|
|
|---|
AVLN Chất lượng tổng thể của cố phiếu Không tốt lắm ( Chất lượng = 54) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
ROE đang giảm đáng kể
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt , ...
| Yếu tố Chất lượng |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 79 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 27.06 |
| PBV / Sector |
5.01 / 4.63
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
7.29 M
|
| Average 1W Daily Value |
5.48 M
GREAT
|
| Yếu tố Kỹ thuật |
|
57% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
37% |
| Lợi tức cho nhà đầu tư |
|
8% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-06 09:08:38 |
| Symbol | AVLN |
| Name | AVALYN PHARMA INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 44.31 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,169.84 / 8,857.28 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 105 W First Street, Boston, MA, United States, 02127
Phone: (206) 707-0340
Website: https://www.avalynpharma.com
Sector: Healthcare >> Biotechnology
Description: Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
